SCHEMBL2897707

SCHEMBL2897707

NC(=S)c1ccc(Br)cc1F

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.66
ALDH1A1 P00352 3/20 0.44
LMNA P02545 3/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 1/20 0.42
ALOX12 P18054 2/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40
KDM1A O60341 2/20 0.39
KDM1B Q8NB78 1/20 0.39
FLT1 P17948 1/20 0.39
FLT4 P35916 1/20 0.39
KDR P35968 1/20 0.39
SLC6A4 P31645 1/20 0.38
CTSL P07711 4/20 0.37
PARP15 Q460N3 1/20 0.37
PARP10 Q53GL7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15609067 0.83 DGAT1 (0.50) DGAT1ALDH1A1LMNANPC1RAB9A
SCHEMBL150293 0.79 DGAT1 (1.00) DGAT1ALDH1A1LMNANPC1RAB9A
SCHEMBL1528166 0.79 DGAT1 (0.66) DGAT1ALDH1A1LMNANPC1RAB9A
SCHEMBL20560720 0.79 DGAT1 (0.55) DGAT1ALDH1A1LMNANPC1RAB9A
SCHEMBL2034076 0.78 CES2 (0.56) DGAT1ALDH1A1GAAHPGD
Hydrochloric Acid SCHEMBL26618126 0.78 DGAT1 (0.96) DGAT1ALDH1A1LMNANPC1RAB9A
Hydrochloric Acid SCHEMBL1484973 0.78 DGAT1 (0.63) DGAT1ALDH1A1LMNANPC1RAB9A
SCHEMBL11821361 0.77 ALDH1A1 (0.45) DGAT1ALDH1A1SMN1; SMN2KMT2AHPGD
SCHEMBL3666515 0.77 ALDH1A1 (0.42) DGAT1ALDH1A1GAAKMT2AHPGD
SCHEMBL31493221 0.77 ALDH1A1 (0.42) DGAT1ALDH1A1GAAKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3860994-B1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE UNIV BRITISH COLUMBIA (CA) 2024-08-14 EP disclosed
US-20220106304-A1 Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2022-04-07 US disclosed
EP-3860994-A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE The University of British Columbia (CA) 2021-08-11 EP disclosed
WO-2020069625-A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2020-04-09 WO disclosed
US-20100286211-A1 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES LIMITED (IN) 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286211-A1 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS OXA1L, PDK4, MLYCD DGAT1 4245/4885ALDH1A1 944/4885LMNA 3677/4885
US-20220106304-A1 Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use BRDT, CBFB, CREBBP DGAT1 3117/4885ALDH1A1 3522/4885LMNA 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.